Hovid Berhad

We are a global pharmaceutical company with 79 years of experience. We strive to improve lives through quality products with continuous innovation.

Being headquartered in Ipoh, Malaysia, we have two regional offices respectively in Hong Kong and the Philippines. Our core business is  in the areas of research and development (R&D), manufacturing, sales and distribution of pharmaceutical products.

Hovid manufactures and distributes more than 400 products, comprising generic drugs, Over- the-counter (OTC) drugs, health supplements and consumer products.

We offer products with research focused  innovations and contract manufacturing services too. Our products are being distributed to 50 countries and hold 1,504 marketing authorisations worldwide.

HYH Herbal Tea

The Ho Yan Hor (HYH), famous household brand of Chinese herbal tea since 1941 was established by our founder, Dr. Ho Kai Cheong, the father  of David Ho. The health tea is well-known in relieving body heat and curing common cold, by promoting self-healing. During post World War II, HYH herbal tea became a popular alternative to western medicine due to its effective relief to common cold. The Asian Flu pandemic of 1957 spread was first identified in East Asia and that subsequently spread to countries worldwide. The outbreak caused an estimated one million to two million deaths.

HYH offered the solution and became the  most sought after household brand at that time to maintain family health until today.

David Ho, the Managing Director of Hovid is  a registered pharmacist who succeeded his father and managed the company since 1980. He transformed the herbal tea business into a modern, GMP certified, global pharmaceutical manufacturing company, that Hovid is known as today.

We are proud to be the pioneer for the  followings:

• FIRST to develop Chinese Herbal Tea in tea bag for easy consumption 
• FIRST to develop the self-emulsifying “SupraBio System” for improved absorption of palm tocotrienols in the human body
• FIRST Malaysian company to export pharmaceuticals to worldwide
• FIRST Palm Tocotrienol publication in the renowned STROKE journal
• FIRST Malaysian pharmaceutical manufacturer to introduce Pick to Light Logistic System for improving the accuracy and effectiveness of daily operation
• FIRST to establish Malaysia’s largest private Bio-Equivalence study centre

Hovid’s quality standards have been routinely inspected and certified by more than 100 audits by various health authorities worldwide. Among them includes the National Pharmaceutical Regulatory Agency (NPRA), the US Food and Drug  Administration (US FDA), the Health Sciences Authority of Singapore and many more since 1980.

In the practice of pharmaceutical quality system,  Hovid strictly complies with Zero Compromise Policy. We ensure the efficacy and potency of medicine and health supplements are delivered at our best efforts. Hovid strives to build a culture of Quality Excellence within the organisation, to provide the best quality healthcare products for greater quality of life for people.

Hovid has also been certified with 1,500 marketing authorisations worldwide. Our manufacturing facilities fulfill the highest levels of quality control and assurance, conforming  to PIC/s, cGMP & GLP guidelines. Our quality control laboratories are certified under ISO/IEC GUIDE 25 and well-equipped with modern and sophisticated instruments for the analysis of finished products, raw and packaging materials.

The manufacturing facilities in Perak are located at two sites, Ipoh and Chemor. Our Chemor plant has gone through recent expansion, where we have introduced high speed and large scale machines to increase our tablet and capsule production capacity by 30%.

We have invested nearly RM45 million on the new plant A which is 30% bigger than existing plant B. In addition, the new plant is designed to meet the pharmaceutical production standards of Europe, the US FDA and Australian TGA (Therapeutic Goods Administration).

The manufacturing activities include  the production of Oral Solid Dosage, the preparation for Oral Liquid Dosage, Topical, Herbal Tea, Penicilin and Softgel Encapsulation.

Hovid possess strong product pipeline and  new R&D centre for better quality, efficacy and safety. Our R&D team comprises a group of 40 professional scientists and laboratory executives, who have completed self-conducted 62 bioequivalence (BE) studies, with an average of 16 products launched per year and 114 products in the R&D pipeline.

With the new R&D centre at Bayan Lepas, Penang, we are able to accommodate the increasing market needs of BE studies for  new product development. As part of clinical assurance, BE ensures the quality, efficacy and safety of pharmaceutical products meet the requirements. Among the main activities conducted at Attest Research (R&D Centre) are product development, drug delivery system, stability study and testing, and clinical services.